Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524572 | NSE Symbol : | ISIN : INE117D01018 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
04-Jul-2025	04-Jul-2025	Change in Auditors	Outcome of the Board Meeting held on Friday, July 07, 2025.
20-May-2025	23-May-2025	Accounts	Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2025. The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2025 at their meeting held on May 23, 2025. (As per BSE Announcement Dated on 23/05/2025)
07-Feb-2025	12-Feb-2025	Quarterly Results	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the unaudited Financial results (Standalone and Consolidated) for the quarter and nine months ended December 31 2024. This is to inform you that Board of Directors in their meeting held today i.e. February 12, 2025 considered and approved the re-appointment of Mr.Venu Madhava Kaparthy (DIN: 00021699) as Whole Time Director designated as Executive Director of the Company and Ms.Mini Manikantan (DIN: 09663184) as Whole Time Director designated as Executive Director of the Company Subject to approval of the members of the Company. Unaudited Financial Results For The Quarter And Nine Months Ended 31st December 2024 (As Per BSE Announcement dated on 12.02.2025)
07-Nov-2024	13-Nov-2024	Quarterly Results	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th September 2024. Financial Results for the Quarter and Half year ended September 30, 2024 (As Per BSE Announcement Dated on: 13/11/2024)
20-Aug-2024	28-Aug-2024	AGM	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/08/2024 inter alia to consider and approve the Audited Financial Statements (Standalone & Consolidated) for the year ended 31st March 2024 the Directors Report for the year ended 31st March 2024 Notice of 35th Annual General Meeting(AGM)and other AGM related matters. Outcome of the Board Meeting held on 28th August 2024, for approval of Annual Financial Statements for the financial year 2023-24 and AGM related matters. (As per BSE Announcement Dated on 28/08/2024)
05-Aug-2024	13-Aug-2024	Quarterly Results	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone & Consolidated) for the quarter and three months ended 30th June 2024. Financial Results (Standalone & Consolidated) for the quarter and three months ended 30th June 2024. Intimation of Appointment of Mr. Prasanna Subramanya Bhat (Membership No. A48828) as Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company with effect from 14th August 2024. (As Per BSE Announcement dated on 13.08.2024)
20-May-2024	28-May-2024	Accounts	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve the Audited Financial Results (Standalone & Consolidated) for the quarter and Year ended 31st March 2024 The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2024 at their meeting held on May 28, 2024. This is to inform you that the Board of Director in their meeting held on Tuesday, May 28, 2024 considered and approved the appointment of Mr.Kashinath Sahu as Secretarial Auditor of the Company and T.N. Raghavendra as Internal Auditor of the Company. Read less.. (As Per BSE Announcement Dated on 28.05.2024)
23-May-2024	23-May-2024	Change in Directors	This is to inform you that the Board of Directors of our material subsidiary 'Adita Bio Sys Private Limited' in their meeting held on Thursday, 23rd May 2024, considered and approved the appointment of Mr.Methuku Nagesh (DIN: 01634324) as an Independent Director, Dr. Prasad S (DIN: 0009659723) as Non executive Non Independent Director and Mr.Balagangadhara B.C. (DIN: 0009658079) as Non Executive Non Independent Director of the Company subject to approval of members of the Company at the ensuing Annual General Meeting. Further the Board of Directors also noted the resignations of Mr.Samuel Sharmanraj Sourappa (DIN: 7004978), Mr. Chetan Basavaraju (DIN: 8154725) and Mr.Kondapura Jayadevappa Shivakumar (DIN: 10249553) from the positions of the Directors of the Company This is to inform you that the Board of Directors of our material subsidiary 'Adita Bio Sys Private Limited' in their meeting held on Thursday, May 23, 2024 considered and approved Mr.Kashinath Sahu as Secretarial Auditor of the Company for the Financial Year 2024-25. (As Per BSE Announcement Dated on 24/05/2024)
02-Mar-2024	02-Mar-2024	Acquisitions	We hereby inform that Board of Directors of the Company at its meeting held today i.e; March 02, 2024, approved the allotment of 1,28,56,578 fully paid up Equity Shares for the Consideration other than cash on Preferential Basis by way of Private Placement. We hereby inform that Board of Directors of the Company at its meeting held today, i.e, March 02, 2024 approved the allotment of 12856578 fully paid-up Equity Shares for the Consideration other than cash on Preferential Basis by way of Private Placement. The details as required under Regulation 30 of Listing Regulations read with SEBI Circular dated July 13, 2023 are given in the attached intimation.
02-Feb-2024	12-Feb-2024	Quarterly Results	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended 31st December 2023. The Board at its meeting held on 12th February 2024, have considered declaration of financial results for the quarter and nine months ended 31st December 2023 amongst other important matters. (As Per BSE Announcement Dated on: 12/02/2024)
03-Jan-2024	06-Jan-2024	Increase in Authorised Capital	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the meeting of the Borad of Directors of the Company is scheduled to be held on Saturday 06th January 2024. Outcome of the Board meeting held on saturday, 06 January 2024. (As per BSE Announcement Dated on 06/01/2024) This is to inform you that Board of Directors in their meeting held on Saturday, 06, 2024, considered and approved the appointment of Dr. Shankarappa Vinaya Babu (DIN:01373832) as Director and Chairman (Non-Executive & Non-Independent) of the Company subject to the approval of the members of the company at the ensuing General Meeting of the Company. Further, Board of Directors has approved the appointment of Dr. Prasad S as Chief Executive Officer (''CEO'') of the company in the category of Key Managerial Personnel. Outcome of the Board meeting held on saturday, 06 January 2024. (As per BSE Announcement Dated on 06/01/2024) Intimation of Alteration in Object Clause and Capital Clause of the Memorandum of Association of the Company. (As Per BSE Announcement dated on 07.01.2024) Further to our intimation dated 06th January 2024, The Company has executed agreements with the shareholders for purchase of shares of Adita Bio Sys Private Limited. (As Per BSE Announcement Dated on 09.01.2024)
04-Nov-2023	11-Nov-2023	Quarterly Results	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2023 inter alia to consider and approve Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2023. Outcome of the Board Meeting held on 11th September , 2023 for approval of unaudited Standalone and Consolidated financial results for the quarter and half year ended 30th September 2023. (As Per BSE Announcement dated on 11.11.2023)
22-Aug-2023	29-Aug-2023	AGM	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2023 inter alia to consider and approve the Audited Financial Statements (Standalone & Consolidated) for the year ended 31st March 2023 the Directors Report for the year ended 31st March 2023 To appoint a Scrutinizer to ascertain Voting Process of 34th Annual General Meeting of the Company To approve draft Notice of 34th Annual General Meeting (AGM) and to decide the date time and venue of the AGM To consider and fix Record date and/or Book closure date for the purpose of 34th Annual General Meeting. Outcome of the Board Meeting held on 29th August , 2023 for approval of Annual Financial Statements for the financial year 2022-23 and AGM related matters. Disclosure under Regulation 30 of SEBI Listing Regulations, 2015. the Baord in its meeting held on 29th Aug 2023, approved the appointment of Mr. Shreedhara Shetty, as Additonal Director in the Category of Non-executive Non-independent Director, Considered resignation of Mr. Venkata Rao Sadhanala as Non-executive Non-Independent Director, Re-appointment of PPKG & Co., Chartered Accountants as Statutory Auditors of the Company. (As Per BSE Announcement Dated on 29/08/2023)
28-Jul-2023	04-Aug-2023	Quarterly Results	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2023 inter alia to consider and approve Unaudited Financial Results for the quarter and three months ended 30th June 2023. PHARMAIDS PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 04 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. (As Per BSE Announcement Dated on 01/08/2023) Outcome of the Board Meeting held on 04th August , 2023 for approval of unudited Standalone and Consolidated financial results for the quarter ended 30th June 2023. M/s Kashinath Sahu & Co., Practicing Company Secretaries has been re-appointed as a secretarial auditor of the company for the financial year 2023-2024. Pursuant to the provisions of regulation 30 and 31A(8) of the Listing Regulations, we wish to inform you that the board at its meeting held today, i.e., 04th August 2023, has inter alia considered and approved the request for reclassfication of Five promoters from 'Promoter/promoter Category' to 'Public Category'. Details of which is provided in the enclosed minutes. (As per BSE Announcement Dated on 04/08/2023)
23-May-2023	29-May-2023	Accounts	PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Audited Financial Results for the Quarter and Year ended 31st March 2023. Outcome of the Board Meeting held on 29th May, 2023 for approval of Audited Standalone and Consolidated financial results (As Per BSE Announcement Dated on 29.05.2023) Pursuant to the provisions of Regulations 30 and 31A(8) of the Listing Regulations and our board meeting outcome dated 29th May 2023, we wish to inform you that the Board, at its meeting held on 29th May 2023, has inter alia considered and approved the respective request letters received from Ms.Umadevi Babulal Jain and Mr.Babulal Jain, persons belonging to the promoter and promoter group of the Company, seeking re-classification from the ''promoter and promoter group'' category to ''public'' category shareholder. subject to approval of the stock exchanges where the equity shares of the Company are listed namely, i.e., BSE Limited. (As Per BSE Announcement Dated on 13.06.2023)

1 2 3

LOGIN HERE

Pharmaids Pharmaceuticals Ltd

Board Meeting